Peregrine Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Peregrine Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-39,608	Closed	-$3.26M	–	348
2022 Q1	$3.26M	Sell	39,608 -2,851	-7%	-$292K	0.08%	252
2021 Q4	$6.23M	Buy	42,459 +1,200	+3%	+$186K	0.12%	242
2021 Q3	$7.3M	Sell	41,259 -23,902	-37%	-$3.85M	0.15%	235
2021 Q2	$10.5M	Buy	65,161 +4,774	+8%	+$767K	0.19%	228
2021 Q1	$10.3M	Buy	+60,387	New	+$12M	0.19%	229

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Peregrine Capital Management's MRTX Position: Q2 2022 in Review

Peregrine Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 39,608 shares — an estimated $3.26M sold.

Peregrine Capital Management first reported a position in MRTX in Q1 2021 and held it in 5 quarters. The position peaked at $10.5M in Q2 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

Peregrine Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Peregrine Capital Management sold 39,608 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3.26M.
Peregrine Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Peregrine Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $10.5M in Q2 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Peregrine Capital Management's 13F filing for Q2 2022, filed 20 Jul 2022.